Uses
Fluocinonide Topical Solution USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Source: US FDA prescribing information
- Presentations
- 6
- Brands
- 0
- Manufacturers
- 0
- Available from stock
- 0
Fluocinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as cream, topical solution and ointment. MedsAcross supplies Fluocinonide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Corticosteroid, Corticosteroid Hormone Receptor Agonists
- ATC classification
- C05AA11 Fluocinonide · Vein and capillary protectors, subgroup C05A, subgroup C05AAD07AC08 Fluocinonide · Corticosteroids for the skin, subgroup D07A, subgroup D07AC
- US FDA first approval
- 30 June 1971
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Topical
- Dosage forms
- Cream, Topical solution, Ointment, Gel
- Identifiers
- UNII 2W4A77YPANRxCUI 4462CAS 356-12-7DrugBank DB01047Q5462791
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
Fluocinonide Topical Solution USP, 0.05% is generally applied to the affected area as a thinfilm from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Source: US FDA prescribing information
Contraindications
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Source: US FDA prescribing information
Warnings and precautions
General Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitaryadrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, the addition of occlusive dressings, and dosage form. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Source: US FDA prescribing information
Side effects
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria
Source: US FDA prescribing information
Storage
Store at 20°- 25°C (68°- 77°F). Avoid excessive heat, above 40°C (104°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
6 presentations of Fluocinonide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Fluocinonide 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| Fluocinonide 0.5 mg/mL topical solutionTopicalGeneric name | — | US FDA | Available on request |
| Fluocinonide 0.1% creamTopicalGeneric name | — | US FDA | Available on request |
| Fluocinonide 0.05% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Fluocinonide 0.005% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Fluocinonide 0.05% gelTopicalGeneric name | — | US FDA | Available on request |
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 June 1971 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Fluocinonide in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Fluocinonide available for export from India?
Yes, on request. MedsAcross lists 6 presentations of Fluocinonide and sources them for licensed hospitals, importers and physicians against valid import documents.
Is Fluocinonide approved by the US FDA?
Yes. The US FDA first approved Fluocinonide on 30 June 1971, according to Drugs@FDA.
Does Fluocinonide need cold chain shipping?
No listed presentation of Fluocinonide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Fluocinonide in?
Fluocinonide is classified under ATC code C05AA11 (Fluocinonide).
References
- Fluocinonide prescribing information (Saptalis Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 11 May 2026
Request Fluocinonide for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.